CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences, Inc (NASDAQ: ENVB), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders, today announced that it has signed a non-binding term sheet with an undisclosed biotechnology development and commercialization company (“Licensee”) to exclusively out-license two patent families of Methods for Treating Breast Cancer and Other Cancers for development through additional discovery and preclinical stages using cannabinoids in combination with chemotherapeutic drugs to treat cancer..

马萨诸塞州剑桥市。-（商业新闻短讯）--Enveric Biosciences，Inc（NASDAQ:ENVB）是一家致力于开发用于治疗抑郁症，焦虑症和成瘾症的新型神经塑性小分子疗法的生物技术公司，今天宣布，它已与一家未公开的生物技术开发和商业化公司（“被许可方”）签署了一份不具约束力的条款清单，专门授权两个专利家族的乳腺癌和其他癌症治疗方法，通过使用大麻素联合化疗药物治疗癌症的额外发现和临床前阶段进行开发。。

In an historic move on Tuesday April 30, 2024, the Biden administration moved to reschedule marijuana, one source of cannabinoids, as a Schedule III controlled substance. The action followed study by the U.S. Department of Health and Human Services (“HHS”), recommendations by both HHS and the Department of Justice (“DOJ”), and support from the U.S.

2024年4月30日星期二，拜登政府采取了一项历史性举措，将大麻（大麻素的一种来源）重新定为第三类管制物质。这项行动是在美国卫生与公众服务部（HHS）的研究、HHS和司法部（DOJ）的建议以及美国的支持下进行的。

Drug Enforcement Agency (“DEA”) that acknowledge the medical benefits of this class of drugs. Enveric applauds the move by the Biden administration which enjoys bi-partisan Congressional support and advances the development of medical uses of much needed drugs..

药品执法机构（“DEA”）承认这类药物的医疗益处。恩维尔克赞扬拜登政府的举措，该举措得到了国会两党的支持，并推动了急需药物的医疗用途的发展。。

Under the terms of the agreement with Enveric, the Licensee will receive an exclusive, global license to the methods, and devices and drugs developed to practice the methods, which feature using cannabinoids in combination with chemotherapeutic drugs and will assume responsibility for all future preclinical and clinical development on a royalty-bearing basis for all human and animal pharmaceutical applications..

根据与Enveric签订的协议条款，被许可方将获得为实施该方法而开发的方法、设备和药物的独家全球许可，该方法的特点是将大麻素与化学治疗药物结合使用，并将承担所有未来临床前和临床开发的责任，并承担所有人类和动物药物应用的版税。。

Assuming certain conditions are met, the Licensee will pay Enveric a License Execution Fee and development and sales milestones up to $61 Million, and royalties (ranging from 2.5% up to 10%) on all future sales. The Licensee also has a cash Buyout Option.

假设满足某些条件，被许可方将向Enveric支付许可执行费、开发和销售里程碑，最高可达6100万美元，以及未来所有销售的版税（2.5%至10%）。被许可方也有现金收购选择权。

Based on preliminary work performed by a renowned UK-based research hospital, it is believed that the methods of using novel treatment regimens that include cannabinoids combinations have potentially a significant impact for patients living with breast and other cancers. It is anticipated that the Licensee may advance these methods into the next stages of development, and further into clinical trials which would demonstrate a major value driver for both Enveric and the Licensee..

根据英国一家著名研究医院进行的初步工作，人们认为使用包括大麻素组合在内的新型治疗方案的方法可能对乳腺癌和其他癌症患者产生重大影响。预计被许可方可能会将这些方法推进下一个开发阶段，并进一步进入临床试验，这将证明Enveric和被许可方的主要价值驱动因素。。

“We are excited to see the Licensee taking this innovative approach in effort to advance a novel treatment based on our discovery,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “We look forward to partnering with the Licensee and are confident in their leadership to translate these discoveries into promising treatments for cancer patients.

Enveric董事兼首席执行官约瑟夫·塔克（JosephTucker）博士说：“我们很高兴看到持牌人采用这种创新方法，努力根据我们的发现推进一种新的治疗方法。”。“我们期待着与被许可方合作，并对他们的领导能力充满信心，将这些发现转化为对癌症患者有希望的治疗方法。

Importantly, this agreement further supports Enveric’s discovery capabilities and its ability to advance novel treatments for cancer and to make them available for others to pursue commercially outside the company with strong future potential upside to Enveric.”.

重要的是，这项协议进一步支持了Enveric的发现能力及其推进癌症新疗法的能力，并使其他人能够在公司之外进行商业追求，这对Enveric具有强大的未来潜力。”。

Breast Cancer alone has approximately 311,000 new cases diagnosed annually in the US, and over 4 million women have a history of, or are in treatment, for breast cancer in the US. The licensed methods also apply to many other forms of cancer that afflict millions more patients in the US.

仅乳腺癌一项，美国每年就诊断出约311000例新病例，美国有400多万女性有乳腺癌病史或正在接受治疗。许可的方法也适用于许多其他形式的癌症，这些癌症在美国折磨着数百万患者。

About Enveric Biosciences

关于Enveric Biosciences

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of New Chemical Entities for specific mental health indications.

Enveric Biosciences（纳斯达克：ENVB）是一家生物技术公司，致力于开发用于治疗抑郁症，焦虑症和成瘾症的新型神经可塑性小分子疗法。利用其独特的发现和开发平台Psybrary™，Enveric为特定的心理健康适应症创建了强大的新化学实体知识产权组合。

Enveric’s lead program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. Enveric is also developing EB-002, formerly EB-373, a next generation synthetic prodrug of the active metabolite, psilocin, being studied as a treatment of psychiatric disorders.

Enveric的领先项目EB-003是治疗难以解决的心理健康障碍的一流方法，旨在促进神经可塑性而不会引起患者产生幻觉。Enveric还在开发EB-002，以前称为EB-373，它是活性代谢物psilocin的下一代合成前药，正在研究用于治疗精神疾病。

Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com..

Enveric总部位于佛罗里达州那不勒斯，在马萨诸塞州剑桥和加拿大卡尔加里设有办事处。有关更多信息，请访问www.enveric.com。。

Forward-Looking Statements

前瞻性声明

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information.

本新闻稿包含适用证券法含义内的前瞻性声明和前瞻性信息。这些陈述与未来事件或未来表现有关。除历史事实陈述外的所有陈述都可能是前瞻性陈述或信息。

Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,” “expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved.

一般来说，前瞻性陈述和信息可以通过使用前瞻性术语来识别，例如“计划”、“预期”或“不预期”、“提议”、“预期”、“预算”、“计划”、“估计”、“预测”、“打算”、“预期”或“不预期”或“相信”，或通过使用声明某些行动、事件或结果可能、可能、应该、将会或可能发生或实现的词语或短语。

Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: negotiate and finalize definitive agreements based on the out-licensing term sheets and perform pursuant to the terms thereof; carry out successful clinical programs in Australia; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential.

前瞻性陈述可能包括历史陈述和关于未来信念、计划、期望或意图的陈述，并基于管理层的信念以及管理层做出的假设和目前可获得的信息。由于某些因素，实际结果可能与前瞻性声明所预期的结果存在重大差异，包括但不限于Enveric的能力：根据out licensing条款清单谈判和最终确定最终协议，并根据其条款执行；在澳大利亚开展成功的临床项目；实现技术开发所预期的价值创造；避免延误计划的临床试验；确定潜在产品在临床前或临床试验中有效或安全；建立或维持合作，以开发治疗候选人；获得适当或必要的政府批准以发挥市场潜力。

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law..

关于这些因素和其他因素的讨论，包括与Enveric有关的风险和不确定性，请参阅Enveric向证券交易委员会提交的文件，包括Enveric在表格10-K中的年度报告和在表格10-Q中的季度报告。除法律要求外，Enveric不打算或有义务修改任何前瞻性声明，无论是由于新信息、未来事件还是其他原因。。